Immunovant (IMVT) Form 3 Immunovant / Michael Geffner ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Geffner Michael

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

320 W 37TH STREET, 6TH FLOOR

(Street)

NEW YORK NY 10018

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/16/2024

3. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Medical Officer*

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock(1)	100,000(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	01/17/2024	01/17/2033	Common Stock	150,000(3)	18.06	D

Explanation of Responses:

1. Represents the number of shares underlying restricted stock units awards ("RSUs").

2. On January 17, 2023, the holder was granted 100,000 RSUs. The RSUs vest over four years, with 25% of the RSUs vesting on January 17, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

3. On January 17, 2023, the holder was granted 150,000 stock options. Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on January 17, 2024 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Remarks:

* The Issuer's Board of Directors appointed the Reporting Person as a Chief Medical Officer of the Issuer effective January 16, 2024. William Macias, M.D. will remain with the Issuer as a Chief Medical Officer. The Reporting Person and Dr. Macias will share Chief Medical Officer responsibilities as the Issuer expands its scope of clinical development activities. In addition, refer to Exhibit 24 - Power of Attorney.

	/s/ Eva Renee Barnett, attorney-in-fact for Michael Geffner	01/16/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.